Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats.
OBJECTIVE
The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2.


METHODS
Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks.


RESULTS
The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP.


CONCLUSIONS
rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study.
Resident, Department of Periodontology, Research Institute for Periodontal Regeneration, College of Dentistry, Yonsei University, Seoul, Korea.
Ji-Woong
JW
Jang
Jeong-Ho
JH
Yun
Kwang-Il
KI
Lee
Ju-Woong
JW
Jang
Ui-Won
UW
Jung
Chang-Sung
CS
Kim
Seong-Ho
SH
Choi
Kyoo-Sung
KS
Cho
D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage / Q000494:pharmacology*; D018786:Bone Substitutes / Q000494:pharmacology*; D004337:Drug Carriers; D006882:Hydroxyapatites / Q000494:pharmacology*; D010012:Osteogenesis / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D012886:Skull / Q000000981:diagnostic imaging / Q000601:surgery; D055114:X-Ray Microtomography
D055396:Bone Morphogenetic Protein 2; D018786:Bone Substitutes; D004337:Drug Carriers; D006882:Hydroxyapatites; D011994:Recombinant Proteins; C074950:hydroxyapatite-beta tricalcium phosphate